Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avalo Therapeutics ( (AVTX) ) has shared an update.
On May 5, 2026, Avalo Therapeutics entered into an underwriting agreement to sell 19,730,000 shares of common stock and 1,400,000 pre-funded warrants at roughly $17.75 per unit, with underwriters exercising in full a 3,169,500-share option on May 6, 2026. The company, which had 29,326,347 shares outstanding as of May 4, 2026, expects to raise about $405 million in net proceeds from the offering, which is expected to close on May 7, 2026, subject to customary conditions.
Avalo plans to use the proceeds, together with existing cash and investments, to advance the clinical development of its lead drug candidate abdakibart, including funding through its Phase 3 topline data release, as well as for working capital and general corporate purposes. The structure of the pre-funded warrants includes ownership limits and immediate exercisability, reflecting an effort to accommodate large investors while managing concentration of ownership in the company’s common stock.
The most recent analyst rating on (AVTX) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.
Spark’s Take on AVTX Stock
According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.
The score is held back primarily by very weak financial performance (minimal revenue, large losses, and significant cash burn). Offsetting this, technicals show strong upward momentum and recent corporate updates were positive—especially the strong Phase 2 readout—though valuation remains challenging due to ongoing unprofitability.
To see Spark’s full report on AVTX stock, click here.
More about Avalo Therapeutics
Avalo Therapeutics, Inc. is a biopharmaceutical company focused on developing clinical-stage therapies, including its lead candidate abdakibart. The company uses public equity offerings to fund late-stage clinical development and related working capital needs, positioning itself as a developer of innovative treatments in the healthcare sector.
Average Trading Volume: 1,133,286
Technical Sentiment Signal: Sell
Current Market Cap: $582.6M
See more data about AVTX stock on TipRanks’ Stock Analysis page.